[Fatal interstitial lung disease associated with maximum androgen blockade]

Rev Med Chil. 2016 Oct;144(10):1356-1359. doi: 10.4067/S0034-98872016001000017.
[Article in Spanish]

Abstract

Maximum androgen blockade is the standard endocrine treatment for advanced prostate cancer. Interstitial lung disease in different degrees of severity, with low mortality and excellent response to treatment may appear with its use. We report a 77 years old patient with advanced prostate cancer who developed severe and progressive respiratory failure associated to bilateral pulmonary infiltrates, attributed to the direct effect of maximum androgen blockade. Despite the therapeutic efforts, the patient died. Lung pathology revealed Usual Interstitial Pneumonia.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Aged
  • Androgen Antagonists / adverse effects*
  • Anilides / adverse effects
  • Antinematodal Agents / adverse effects*
  • Biopsy
  • Disease Progression
  • Fatal Outcome
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / pathology
  • Male
  • Nitriles / adverse effects
  • Prostatic Neoplasms / drug therapy
  • Tomography, X-Ray Computed
  • Tosyl Compounds / adverse effects

Substances

  • Androgen Antagonists
  • Anilides
  • Antinematodal Agents
  • Nitriles
  • Tosyl Compounds
  • bicalutamide